|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
This uncertainty reflects the fact that most prospective clinical trials of EGFR TKIs have been restricted to patients with tumor harboring common (Del19 or L858R) mutations.
|
31558282 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
T790M coexisted with L858R mutation (8/11) more than with deletions in exon 19 (19del) mutation (3/11) in TKI-naive tumors, while 19del co-occurred as often as L858R in post-TKI tumors.
|
31463130 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, the median PFS (P=0.005) and OS (P=0.002) of patients carrying the EGFR exon 21 L858R mutation was significantly decreased in patients with tumors where ERβ1 cytoplasmic expression was high.
|
31289556 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreated advanced NSCLC with tumors harboring exon 19 deletion (Ex19del)/L858R EGFR TKI-sensitizing mutations.
|
30240852 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR T790M mutation, which conveys resistance to in the present study, [<sup>18</sup> F]FEWZ was assessed in vitro to determine efficacy relative to the starting compound and in vivo to measure the biodistribution and specificity of binding to EGFR wild-type, L858R and T790M bearing tumours.
|
31132309 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
It is approved for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, and for patients with T790M-positive advanced NSCLC whose disease has progressed on or after EGFR-TKI therapy.
|
30875094 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
NGS of plasma circulating cell-free tumor DNA shown that L858R mutation was no longer detectable and the copy number of MET dropped when the patient got remission.
|
30797494 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Finally, we evaluated the concordance between plasma and tumour tissues by simultaneously detecting EGFR L858R by ddPCR and LNA-dPNA PCR clamp in 132 tissues and matched plasma samples from patients with NSCLC.
|
30663747 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no difference for the proportion of the 2 most frequent EGFR mutations (exon 19 deletion and L858R mutation) (P=0.85) or KRAS-mutated codon (P=0.22) between tumors in younger or older patients.
|
30095461 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we report a case of emergent <i>MET</i> amplification detected in a tumor sample from a patient with NSCLC harboring EGFR L858R mutation after disease progression on erlotinib.
|
30881166 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Real-time PCR analysis showed that the right-sided tumor had an epidermal growth factor receptor (EGFR) mutation presenting as point mutation T790M in exon 20, while the left-sided tumor had a point mutation L858R in exon 21 of EGFR.
|
31426797 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Previously, we detected circulating tumor DNA that contained two EGFR mutations (p.L858R and exon19 del) in plasma of patients with late-stage non-small-cell lung carcinoma (NSCLC) using the electric field-induced release and measurement (EFIRM) platform.
|
30309763 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
During the cancer development, sequential DNA sequencing data that used circulating cell-free tumor DNA, and NGS revealed EGFR L858R and T790M mutations, MYC amplification, and other gene variations.
|
30572427 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
This case represents the first evidence that 1) bevacizumab combined with osimertinib can significantly relieve tumor growth and respiratory symptoms in non-small-cell lung cancer patients with osimertinib resistance and 2) the clinical use of osimertinib, bevacizumab, and brigatinib is effective as combination therapy for pulmonary adenocarcinoma in the presence of triple EGFR mutations of L858R, T790M, and <i>cis</i>-C797S.
|
30233215 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
AS-PCR analysis of treatment-naïve tumor samples revealed somatic T790M mutation in 3/394 (1%) non-small cell lung carcinomas (NSCLC) carrying the tyrosine kinase inhibitor (TKI)-sensitizing EGFR mutation, but in none of 334 NSCLC lacking EGFR exon 19 deletions (ex19del) or L858R substitutions and in none of 235 non-lung tumors.
|
30145586 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Significant differences in pathological features associated with the tumor microenvironment were identified in MIA with 19Del or L858R mutations.
|
30546439 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Afatinib is 1 of 3 tyrosine kinase inhibitors approved in the United States for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions (del19) or exon 21 (L858R) substitution mutations.
|
29799327 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Only 1 tumor had the coexistence of L858R mutation and EML4-ALK fusion.
|
27438512 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumors with L858R were associated with a lower CTR (p=0.046), and tended to have a higher incidence of a lepidic growth pattern by pathological evaluation (p=0.073) compared to those with Del-19.
|
28577949 |
2017 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Finally, on PET imaging study using [<sup>18</sup>F]APP-1 with tumor-bearing mice, the H3255 tumor (L858R mutant) was more clearly visualized than the H1975 tumor (L858R/T790M mutant).
|
28435529 |
2017 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two hundred sixteen tumor tissue samples of primarily chemotherapeutic naïve NSCLC patients were analyzed for EGFR mutations E746-A750del and L858R and correlated with DNA-sequencing.
|
29556606 |
2017 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Compared with tumor tissue samples, the sensitivity and specificity of ddPCR were 76.19% (16/21) and 96.55% (28/29) for mutant L858R, and 88.89% (8/9) and 100% (41/41) for ex19del, respectively.
|
28789464 |
2017 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Question 34: Why is epidermal growth factor receptor (EGFR) 19 Del-positive tumor more sensitive to targeted therapy than EGFR 21 L858R-positive tumor in patients with non-small cell lung cancer?
|
28571582 |
2017 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Circulating tumor DNA (ctDNA) is released into the circulation by tumor cell turnover and has been shown to be detectable in urine.<b>Experimental Design:</b> We tested the hypothesis that dynamic changes in EGFR activating (exon 19del and L858R) and resistance (T790M) mutation levels detected in urine could inform tumor response within days of therapy for advanced non-small cell lung cancer (NSCLC) patients receiving osimertinib, a second-line third-generation anti-EGFR tyrosine kinase inhibitor.<b>Results:</b> Eight of nine evaluable NSCLC patients had detectable T790M-mutant DNA fragments in pretreatment baseline samples.
|
28420725 |
2017 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
CHMFL-EGFR-26 bore acceptable pharmacokinetic properties and demonstrated dose-dependent tumor growth suppression in the H1975 (EGFR L858R/T790M) and PC-9 (EGFR del19) inoculated xenograft mouse models.
|
28407693 |
2017 |